Puzzle Medical Devices
Series A in 2025
Puzzle Medical Devices develops innovative heart pump solutions to treat advanced heart failure. Its flagship product, ModulHeart, is a modular percutaneous device designed to reduce cardiac afterload and improve renal perfusion. The device's unique design enables safe percutaneous implantation, supporting both renal and cardiac function with low risk of complications. Puzzle Medical has successfully completed its first-in-human study, demonstrating improvements in cardiac and kidney function.
Axonis Therapeutics
Series A in 2024
Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.
Gladius Pharmaceuticals
Venture Round in 2018
Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.
Opsens Inc. is a Canadian company that specializes in developing, manufacturing, and selling fiber optic sensors for various applications, primarily in interventional cardiology and industrial markets. It operates in two main segments: Medical and Industrial. The Medical segment focuses on physiological measurements, including Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR), and offers products such as the OptoWire, an advanced optical pressure guidewire, and miniature optical sensors for pressure and temperature measurement. These sensors are designed for integration into medical devices, catering to needs in areas like transcatheter aortic valve replacement. The Industrial segment provides fiber optic sensing solutions for diverse applications, including life sciences, energy, and civil engineering. Opsens markets its products through a direct sales force and distributors across the United States, Japan, Canada, and internationally, with its headquarters located in Québec, Canada.
Gladius Pharmaceuticals
Series A in 2015
Gladius Pharmaceuticals Inc. is a biotechnology firm based in Montréal that focuses on developing innovative antibiotics to address life-threatening, multi-drug-resistant bacterial infections. The company is dedicated to creating novel drug candidates that demonstrate broad-spectrum efficacy against gram-negative pathogens. Gladius's antibiotics aim to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby providing physicians with effective treatment options for challenging bacterial infections.